SP-101 is under clinical development by Spirovant Sciences and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SP-101 overview

SP-101 is under development for the treatment of cystic fibrosis. The therapeutic candidate is formulated as an aerosol and administered through inhalation. It comprises of a recombinant chimeric adeno-associated virus vector (AV.TL65) encoding cystic fibrosis transmembrane conductance regulator (CFTR). The therapeutic candidate is developed based on the adeno-associated (AAV) viral gene therapy platform.

Spirovant Sciences overview

Spirovant Sciences is a company that develop novel gene therapies for cystic fibrosis and other pulmonary diseases. The company is headquartered in United States.

For a complete picture of SP-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.